Posted by Michael Wonder on 06 May 2024
Merus announces US FDA acceptance and priority review of biologics license application for zenocutuzumab for the treatment of NRG1 positive NSCLC and PDAC
6 May 2024 - If approved, zenocutuzumab will be the first targeted therapy for NRG1 positive cancer.
Merus today announced that the US FDA has accepted for priority review a biologics license application for the bispecific antibody zenocutuzumab in patients with neuregulin 1 fusion non-small cell lung and NRG1 positive pancreatic cancer.
